에이비엘바이오, ABL503 병용 임상 확대…IND 변경 신청

ABL503's expansion into combination therapy represents a crucial validation milestone for ABL Biotech's GraBoDy-T dual antibody platform in immuno-oncology, where multi-targeted approaches are essential for breakthrough efficacy. By combining 4-1BB and PD-L1 targeting, the strategy significantly increases therapeutic potential and commercial value while opening pathways for technology licensing partnerships. This clinical development pivot positions the company to accelerate market entry and establish valuable out-licensing deals.